Danny Tomka Wyeth WYE-N DON'T BUY Jul 20, 2005

All the big pharma companies are taking out a lot of costs. The problem is the pipeline is pretty lean, visability is lean. Maybe a little bit of a short term trade up to reward them for the reduced cost structure. Not significant.

Danny Tomka

Unlock Rating

$46.280

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

TOP PICK

Have great new pharmaceutical products they will bring into the market in the 2006/2012 timeframe. 14 X earnings and 2 1/2 percent yield. High quality.

BUY

All the major drug stocks are starting to act better. In this type of market, money moves from risky stocks to defensive stocks. A good place to be.

BUY

Pharmaceutical sector is trading at very low valuations. Good growth profile and good portfolio of drugs. Also don’t have the problem of patent expirations that Pfizer does.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Danny Tomka Wyeth WYE-N DON'T BUY Jul 20, 2005

You might be interested:

Wyeth(WYE-N)

Wyeth(WYE-N)

Wyeth(WYE-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Mike Philbrick

Stockchase Insights

Jim Cramer - Mad Money

Stan Wong

The Panic-Proof Portfolio (Stockchase Research)